An interventional study of Sevoflurane in Congenital Heart Disease and Infant, Premature, Diseases, sponsored by Jun Ma. Status unknown at 1 site in China. Open to participants aged Up to 3 Years. Per ClinicalTrials.gov, last updated 2021-02-11.
Sponsored by Jun Ma · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Heart Defects, Congenital with a site in China — 27 open to participants now, 30 under way, none of them phase 3. Heart Defects, Congenital · China.
Among the 79 studies in Heart Defects, Congenital with a site in China, this one is the 29th largest by planned enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2018, is one of 31 with no phase, and was the 27th registered.
991 studies on the registry are indexed under Heart Defects, Congenital; 251 are open to participants now.
Browse Heart Defects, Congenital studies →27 of the 79 studies in Heart Defects, Congenital with a site in China are open now. Recruiting first, the newest first:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages up to 18
Children's Hospital of Fudan University · Sites in China
Ages 0 mo–6 mo
Yan Fuxia · Sites in China
Ages 1 days–3 yrs
Yan Fuxia · Sites in China
Ages 6–12
China National Center for Cardiovascular Diseases · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.
This study: Up to 3 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 5 · Phase 4 2
First in 2000; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 60 across 507 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 160 across the 41 interventional studies, 1,554 across the 38 observational. Of the 30 that completed or were terminated, 3 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 79 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jun Ma as lead sponsor.
Jun Ma has 1 study filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Defects, Congenital with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747546Children's Hospital of Fudan UniversityResearch on Circulation Management Strategy Based on Oxygen Metabolism Balance After CHD Surgery | 2026-12-31 |
| NCT06542120Xinhua Hospital, Shanghai Jiao Tong University School of MedicineResearch on Body Voice AI Recognition System for Children's Health Management | 2026-12-31 |
| NCT07115108Children's Hospital of Fudan UniversityEffectiveness of High-Energy Density Enteral Nutrition for Enhancing Physical Growth and Cognitive Brain Development in Infants With Congenital Heart Disease | 2026-12-31 |
| NCT07854145Shanghai Jiao Tong University School of MedicineStarry-Sky Projection and Maternal Voice for Sleep After Pediatric Cardiac Surgery | 2027-03-31 |
| NCT07375602Xinhua Hospital, Shanghai Jiao Tong University School of MedicineA Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 79 studies in Heart Defects, Congenital with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To observe the effect of sevoflurane on the concentration of S100β and regional cerebral oxygen saturation in infants with congenital heart disease undergoing cardiac surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sevoflurane will be used as a narcotic drug in one group during cardiac surgery.
Drug: Sevoflurane
1.5%-3% Sevoflurane will be given during the cardiac surgery except cardiopulmonary bypass.
Concentration of S100β protein
The concentration of S100β protein was performed using the electrochemiluminescence immunoassay.(Blood samples from patients were drawn from central intravenous.)
Time frame: 5 minutes after tracheal intubation; immediately after cardiopulmonary bypass; immediately after operation; 12 hours, 24 hours postoperative
Level of regional cerebral oxygen saturation(rScO2)
The rScO2 was measured by using noninvasive near-infrared spectroscopy during cardiac surgery
Time frame: 5 minutes after tracheal intubation; immediately after cardiopulmonary bypass; immediately after operation; 12 hours, 24 hours postoperative
Started Jan 2018 (actual). Primary completion is estimated for Dec 2021, 47 months after the start.
Of 205 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 47 months is above that.
Counting every sponsor, half of 223 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sevoflurane